Sender Herschorn, BSc, MDCM, FRCSC, discusses a subgroup analysis of the COURAGE trial showing that vibegron provided comparable efficacy and favorable safety in men 75 years and older with persistent OAB symptoms receiving pharmacotherapy for BPH.
Sender Herschorn, BSc, MDCM, FRCSC
Advertisement
Articles by Sender Herschorn, BSc, MDCM, FRCSC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The Evolving Landscape of Minimally Invasive BPH Therapy
2
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
3
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
4
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
5